It has recently been reported that the deadly Ebola virus has hit the Democratic Republic of the Congo. According to recent reports, there has been about 29 cases and 3 deaths centered in the Congo’s Bas Uele Province near the border of the Central African Republic. While many residents flee affected areas, the WHO speculates costs to reach $10 million. However, the days of an Ebola outbreak beconing a national crisis may be at an end.
According to the World Health Organization, an untested and unlicensed Ebola vaccine could be tested in the Democratic Republic. U.S. Drug manufacturer Merck tested its VSV-EBOV Ebola Vaccine in Guinea at the end of the West African outbreak that ended in January of 2016 showing complete protection against the virus.
In 2015, much earlier than Merck, China had already announced it would begin mass producing an Ebola vaccine which had already been approved for trials in late 2014. During the 2013-2016 West African outbreak, China emerged as a contender in the fight against Ebola, when a report issued by China’s Academy of Military Medical Sciences (AMMS), indicated its rAd5-EBOV Ebola vaccine was safe and effective. According to the report, the vaccine was successful in 500 cases in Sierra Leone.